INDV
Indivior·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
MACD Golden Cross
High Gross Profit Margin
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INDV
Indivior Plc
A global specialty pharmaceutical company and a global leader in the treatment of opioid dependence
10710 Midlothian Turnpike, Suite 125, North Chesterfield , VA 23235
--
Indivior PLC was incorporated as a public limited company under the laws of England and Wales on 26 September 2014. The business of the company is historically developed and managed by Reckitt Group, an independent division of a public limited liability company incorporated under the laws of England and Wales. The company is a global specialty pharmaceutical company and is currently a global leader in the treatment of opioid dependence, with more than 20 years of experience in this field.
Earnings Call
Q2/2025
Estimate EPS0.26
Actual EPS0.51
Estimate Revenue241.67M
Actual Revenue302.00M
Indivior's Q2 2025: Navigating Contradictions in SUBLOCADE Growth, CJS Funding, and Market Dynamics
Aug 02,2025 01:49
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
INDV has released its 2025 Q3 earnings. EPS was reported at 0.72, versus the expected 0.41, beating expectations. The chart below visualizes how INDV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
INDV has released its 2025 Q3 earnings report, with revenue of 314.00M, reflecting a YoY change of 2.28%, and net profit of 42.00M, showing a YoY change of 90.91%. The Sankey diagram below clearly presents INDV's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
